Skip to main content

Articles

Payers' Guide, FDA Approvals

Nuzyra (Omadacycline) Approved for the Treatment of Community-Acquired Bacterial Pneumonia or Acute Bacterial Skin and Skin Structure Infections

Payers' Guide, FDA Approvals

Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination FDA Approved for the Treatment of Waldenström’s Macroglobulinemia

Payers' Guide, FDA Approvals

Olumiant (Baricitinib) Once-Daily Oral Drug Approved for the Treatment of Patients with Moderately to Severely Active Rheumatoid Arthritis

Payers' Guide, FDA Approvals

Ilumya (Tildrakizumab-asmn), Interleukin-23 Antagonist, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis

Payers' Guide, FDA Approvals

Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation

Payers' Guide, FDA Approvals

Eylea (Aflibercept) Receives FDA Approval of New Dose for Age-Related Macular Degeneration

Payers' Guide, FDA Approvals

Tosymra (Sumatriptan) Nasal Spray Approved for the Acute Treatment of Migraine, with or without Aura

Payers' Guide, FDA Approvals

Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer

Payers' Guide, FDA Approvals

Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia

Payers' Guide, FDA Approvals

Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults

Page 56 of 245
Results 551 - 560 of 2441